VIRGINIA RETIREMENT SYSTEMS ET Al Takes Position in BioMarin Pharmaceutical Inc. $BMRN

VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 89,320 shares of the biotechnology company’s stock, valued at approximately $5,111,000.

A number of other large investors also recently bought and sold shares of the business. CIBC Private Wealth Group LLC boosted its position in BioMarin Pharmaceutical by 38.2% during the fourth quarter. CIBC Private Wealth Group LLC now owns 648 shares of the biotechnology company’s stock worth $39,000 after purchasing an additional 179 shares in the last quarter. Northwestern Mutual Investment Management Company LLC increased its position in shares of BioMarin Pharmaceutical by 0.4% in the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 42,982 shares of the biotechnology company’s stock valued at $2,554,000 after buying an additional 183 shares in the last quarter. Caerus Investment Advisors LLC raised its stake in shares of BioMarin Pharmaceutical by 2.8% during the 4th quarter. Caerus Investment Advisors LLC now owns 10,236 shares of the biotechnology company’s stock worth $608,000 after buying an additional 278 shares during the period. Chicago Partners Investment Group LLC raised its stake in shares of BioMarin Pharmaceutical by 2.4% during the 1st quarter. Chicago Partners Investment Group LLC now owns 12,183 shares of the biotechnology company’s stock worth $660,000 after buying an additional 290 shares during the period. Finally, Parallel Advisors LLC lifted its position in shares of BioMarin Pharmaceutical by 62.2% during the 3rd quarter. Parallel Advisors LLC now owns 769 shares of the biotechnology company’s stock valued at $42,000 after buying an additional 295 shares in the last quarter. Institutional investors and hedge funds own 98.71% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on BMRN shares. Canaccord Genuity Group lifted their price target on shares of BioMarin Pharmaceutical from $111.00 to $114.00 and gave the company a “buy” rating in a research note on Monday, August 10th. Bank of America dropped their target price on shares of BioMarin Pharmaceutical from $85.00 to $80.00 and set a “buy” rating on the stock in a research report on Tuesday, May 19th. UBS Group set a $88.00 price target on shares of BioMarin Pharmaceutical in a research note on Wednesday, August 26th. BMO Capital Markets began coverage on BioMarin Pharmaceutical in a report on Wednesday, August 19th. They issued an “outperform” rating and a $98.00 price objective on the stock. Finally, Wall Street Zen raised BioMarin Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $89.17.

BioMarin Pharmaceutical Stock Down 2.9%

Shares of NASDAQ BMRN opened at $64.63 on Wednesday. The company has a market capitalization of $12.51 billion, a P/E ratio of 174.68, a P/E/G ratio of 0.48 and a beta of 0.24. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.39 and a quick ratio of 1.32. The company has a 50 day simple moving average of $62.90 and a 200-day simple moving average of $58.43. BioMarin Pharmaceutical Inc. has a 1 year low of $49.26 and a 1 year high of $70.98.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, beating analysts’ consensus estimates of $0.95 by $0.25. The firm had revenue of $989.71 million for the quarter, compared to analysts’ expectations of $932.03 million. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%.The firm’s quarterly revenue was up 20.0% on a year-over-year basis. During the same period in the prior year, the firm posted $1.44 earnings per share. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. On average, equities research analysts predict that BioMarin Pharmaceutical Inc. will post 4.1 earnings per share for the current year.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.